Cefepime is a fourth generation intravenous cephalosporin antibiotic developed in 1994. Cefepime has broad spectrum activity against Gram positive and Gram negative bacteria. It has good activity against Pseudomonas aeruginosa, Staphylococcus aureus, and multiple drug resistant Streptococcus pneumoniae. A particular strength is its activity against Enterobacteriaceae. more...
Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front line agent when infection with Enterobacteriaceae is known or suspected. Cefepime is commonly used to treat severe nosocomial pneumonia and neutropenic fever.
Cefepime is marketed under the trade names Maxipime, Maxcef, Cepimax, Cepimex, and Axepim.
Read more at Wikipedia.org